Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › XTLB Leadership & Pay · Oct 14, 2026
XTL Biopharmaceuticals appoints Gilai Dolev to replace Iris Shapira Yalon on Board XTLB Xtl Biopharmaceuticals Ltd
Iris Shapira Yalon resigned from the board for personal reasons, effective upon shareholder approval of her successor or November 20, 2026. The company nominated Gilai Dolev as an external director for a three-year term to replace her. XTL Biopharmaceuticals Ltd. develops and commercializes pharmaceutical products.
More from Xtl Biopharmaceuticals Ltd XTL Biopharmaceuticals Ltd. was served with a shareholder motion on August 3, 2026, seeking court authorization to… Aug 5, 2026 XTL Biopharmaceuticals Ltd. received a letter from Nasdaq confirming it has regained compliance with several listing… Jul 21, 2026 XTL Biopharmaceuticals Ltd. consummated its acquisition of Psyga Bio Ltd. on June 30, 2026, acquiring approximately… Jun 30, 2026 On June 29, 2026, shareholders approved the acquisition of 80% to 100% of Psyga Bio Ltd. via the issuance of shares… Jun 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
